荨麻疹和血管性水肿

Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734-66.全文  摘要

Fine LM, Bernstein JA. Guideline of chronic urticaria beyond. Allergy Asthma Immunol Res. 2016 Sep;8(5):396-403.全文  摘要

Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45:547-565.全文  摘要

Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 Jul;77(7):1961-90.全文  摘要

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734-66.全文  摘要

2. Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician. 2017 Jun 1;95(11):717-24.全文  摘要

3. Greaves MW. Chronic urticaria. N Engl J Med. 1995;332:1767-1772. 摘要

4. Amar SM, Dreskin SC. Urticaria. Prim Care. 2008;35:141-157. 摘要

5. Nedelea I, Deleanu D. Isolated angioedema: an overview of clinical features and etiology. Exp Ther Med. 2019 Feb;17(2):1068-72.全文  摘要

6. Fine LM, Bernstein JA. Guideline of chronic urticaria beyond. Allergy Asthma Immunol Res. 2016 Sep;8(5):396-403.全文  摘要

7. Kaplan AP. Urticaria and angioedema. In: Middleton's allergy: principles and practice, vol 2. 6th ed. Philadelphia, PA: Mosby; 2003:1537-1558.

8. Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14:214-220.全文  摘要

9. Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010 Dec;35(8):869-73. 摘要

10. Mahoney EJ, Devaiah AK. Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk? Otolaryngol Head Neck Surg. 2008;139:105-108. 摘要

11. Kostis WJ, Shetty M, Chowdhury YS, et al. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018 Jun 8;20(7):55. 摘要

12. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 May;69(5):602-16. 摘要

13. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):14.全文  摘要

14. Fraser K, Robertson L. Chronic urticaria and autoimmunity. Skin Therapy Lett. 2013 Nov-Dec;18(7):5-9.全文  摘要

15. Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. Allergy. 2017 Oct;72(10):1440-60.全文  摘要

16. Ghazanfar MN, Kibsgaard L, Thomsen SF, et al. Risk of comorbidities in patients diagnosed with chronic urticaria: a nationwide registry-study. World Allergy Organ J. 2020 Jan;13(1):100097.全文  摘要

17. Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006 Oct 24;175(9):1065-70.全文  摘要

18. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161:2417-2429.全文  摘要

19. Jacques P. Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol. 1992;89:1139-1143. 摘要

20. Natbony SF. Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol. 1983;86:759-765. 摘要

21. Brodell LA. Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100:291-298. 摘要

22. Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020 Mar 19;382(12):1136-48. 摘要

23. Maas C, Renné T. Coagulation factor XII in thrombosis and inflammation. Blood. 2018 Apr 26;131(17):1903-9.全文  摘要

24. Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019 Jul 2;80(7):391-8.全文  摘要

25. Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019 Mar 13;14(1):65.全文  摘要

26. Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014 Apr;21(4):469-84.全文  摘要

27. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis - a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-123.全文  摘要

28. Weldon D. When your patients are itching to see you: not all hives are urticaria. Allergy Asthma Proc. 2005;26:1-7. 摘要

29. Kozel MM. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol. 1998;134:1575-1580. 摘要

30. Dice JP. Physical urticaria. Immunol Allergy Clin North Amer. 2004;24:225-246. 摘要

31. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45:547-565.全文  摘要

32. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270-7.全文  摘要

33. Bunselmeyer B, Laubach HJ, Schiller M, et al. Incremental build-up food challenge - a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria: a pilot study: stepwise food challenge in chronic urticaria. Clin Exp Allergy. 2009 Jan;39(1):116-26. 摘要

34. Sabroe RA, Lawlor F, Grattan CEH, et al. British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021. Br J Dermatol. 2022 Mar;186(3):398-413.全文  摘要

35. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022 Jul;77(7):1961-90.全文  摘要

36. Kaplan AP. Urticaria and angioedema. In: Adkinson NF, Bochner B, Busse W, et al, eds. Middleton's allergy: principles and practice, vol 2. 7th ed. Philadelphia, PA: Mosby, 2009;1063-1081.

37. Georgy MS, Pongracic JA. Chapter 22: Hereditary and acquired angioedema. Allergy Asthma Proc. 2012 May-Jun;33 Suppl 1:73-76.全文  摘要

38. Barniol C, Dehours E, Mallet J, et al. Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial. Ann Emerg Med. 2018 Jan;71(1):125-31.e1.全文  摘要

39. Shertzer CL, Lookingbill DP. The effects of relaxation therapy and hypnotizability in chronic urticaria. Arch Dermatol. 1987;123:197-201. 摘要

40. Handa S. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Derm Treat. 2004;15:55-57. 摘要

41. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008 Sep;1(9):145-55.全文  摘要

42. Fein MN, Fischer DA, O'Keefe AW, et al. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.全文  摘要

43. Hindmarch I, Johnson S, Meadows R, et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine, and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin. 2001;17:241-255. 摘要

44. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682.全文  摘要

45. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Derm. 2006;32:34-38. 摘要

46. Sharma M, Bennett C, Cohen SN, et al. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014 Nov 14;(11):CD006137.全文  摘要

47. Brunet C, Bedard PM, Hebert J. Effects of H1-antihistamine drug regimen on the histamine release by nonlesional skin mast cells of patients with chronic urticaria. J Allergy Clin Immunol. 1990;86:787-793. 摘要

48. Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;78:867-873. 摘要

49. Monroe EW, Cohen SH, Kalbfleisch J, et al. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117:404-407. 摘要

50. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol. 1981;68:262-266. 摘要

51. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol. 1998;102:876-877. 摘要

52. Spector S, Tan RA. Antileukotrienes in chronic urticaria. J Allergy Clin Immunol. 1998;101:572. 摘要

53. Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy. 2002;32:1763-1768. 摘要

54. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic urticaria. J Allergy Clin Immunol. 2004;114:619-625. 摘要

55. Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401-1407. 摘要

56. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113:134-140. 摘要

57. Perez C, Sanchez-Borges M, Capriles E, et al. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol. 2001;108:1060-1061. 摘要

58. Food and Drug Administration Drug Safety Communication. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Mar 2020 [internet publication].全文

59. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-935. 摘要

60. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-573. 摘要

61. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019 Jan;155(1):29-38.全文  摘要

62. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018 Feb;141(2):638-49.全文  摘要

63. Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol. 2007 Feb;150(4):509-18.全文  摘要

64. Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporine in chronic 'idiopathic' urticaria. Br J Dermatol. 2000;143:365-372. 摘要

65. Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria, a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55:705-709. 摘要

66. Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):586-99. 摘要

67. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 2. Ann Allergy Asthma Immunol. 2008;100:517-526. 摘要

68. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. NEJM 2010;363:513-522.全文  摘要

69. Bork K, Meng G, Staubach P. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45:1774-1784. 摘要

70. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. NEJM 2010;363:523-531.全文  摘要

71. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41.全文  摘要

72. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013 Jun;131(6):1491-3.全文  摘要

73. Bork K, Hardt J, Staubach-Renz P, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jul;112(1):58-64. 摘要

74. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010 Feb;50(2):354-60. 摘要

75. Longhurst H, Zinser E. Prophylactic therapy for hereditary angioedema. Immunol Allergy Clin North Am. 2017 Aug;37(3):557-70. 摘要

76. Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017 Mar 23;376(12):1131-40.全文  摘要

77. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008 Feb;100(2):153-61. 摘要

78. Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474-481.全文  摘要

79. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742-1750. 摘要

80. Manning ME, Kashkin JM. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. Allergy Asthma Proc. 2021 Jul 14;42(4):274-22.全文  摘要

81. Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9.全文  摘要

82. National Institute for Health and Care Excellence. Berotralstat for preventing recurrent attacks of hereditary angioedema. Oct 2021 [internet publication].全文

83. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018 Nov 27;320(20):2108-21. [Erratum in: JAMA. 2019 Apr 23;321(16):1636.]全文  摘要

84. Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017;7:36.全文  摘要

85. ClinicalTrials.gov. A study of STAR-0215 in healthy adult participants. ClinicalTrials.gov identifier: NCT05477160. Jan 2023 [internet publication].全文

86. ​ClinicalTrials.gov. A study of STAR-0215 in participants with hereditary angioedema. ClinicalTrials.gov identifier: NCT05695248. Aug 2023 [internet publication].全文

87. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019 Oct 3;381(14):1321-32.全文  摘要

88. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012 Feb;129(2):308-20.全文  摘要